Shasun Pharmaceuticals to focus on formulations manufacturing in regulated markets

02 Jun 2014 Evaluate

In a view to become an integrated pharmaceutical company, Shasun Pharmaceuticals is focusing on formulations manufacturing and marketing in the regulated markets. The company is expecting the share of formulations to grow from current 15% of its total revenue to 40% by 2016-17.

Moreover, the company has started efforts to transform into a globally integrated pharmaceutical company from last year. Further, the company is planning to set up its marketing subsidiary in US during the current fiscal year.

In Japan also, the company currently has a marketing capability for APIs, but it would be looking at how to go ahead with formulations in the country.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×